| 章建卫.自拟补肝通络方联合经皮椎间孔镜治疗对椎间盘源性腰痛患者临床症状、血清6-keto-PGF1 α、Th17细胞相关细胞因子的影响[J].浙江中西医结合杂志,2025,35(1): |
| 自拟补肝通络方联合经皮椎间孔镜治疗对椎间盘源性腰痛患者临床症状、血清6-keto-PGF1 α、Th17细胞相关细胞因子的影响 |
|
| 投稿时间：2024-03-21 修订日期：2024-11-19 |
| DOI： |
| 中文关键词: 椎间盘源性腰痛 自拟补肝通络方 经皮椎间孔镜 血清6-酮-前列腺素F1α 辅助性T细胞17 |
| 英文关键词:Discogenic low back pain Self-designed Bugantongluo prescription Percutaneous transforaminal endoscopic discectomy Serum 6-keto-prostaglandin F1-α Helper T cell 17 |
| 基金项目:课题:温岭市科技项目,(编号:2019S0180090) |
|
| 摘要点击次数: 373 |
| 全文下载次数: 7 |
| 中文摘要: |
| 目的: 探讨椎间盘源性腰痛患者采用自拟补肝通络方联合经皮椎间孔镜治疗的联合疗法的价值,分析对其临床症状、血清6-酮-前列腺素F1α(6-keto-PGF1 α)、辅助性T细胞17(Th17)细胞相关细胞因子的影响。方法:2022年3月~2023年3月期间于本院收治的105例椎间盘源性腰痛患者,采用随机数表法分为对照组(n=52)和观察组(n=53),对照组予经皮椎间孔镜及常规治疗,观察组在其基础上给予自拟补肝通络方治疗,两组均治疗3月。观察两组疗效、治疗前后中医证候积分变化、腰腿部疼痛情况和恢复情况以及6-keto-PGF1 α、Th17细胞相关细胞因子水平变化,并监测不良反应。结果:①观察组治疗3月后腰部疼痛,肢体麻木,腰膝酸软、屈伸无力等证候积分等证候积分均低于对照组(P<0.05)；②观察组总有效率高于对照组(P<0.05)；③治疗1月及3月后,观察组疼痛视觉模拟评分(VAS)及Oswestry功能障碍指数(ODI)均低于对照组(P＜0.05)。④治疗3月后,观察组患者6-keto-PGF1 α、Th17细胞水平及白细胞介素-6(IL-6)、白细胞介素17(IL-17)水平均低于对照组(P＜0.05)。⑤两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:自拟补肝通络方联合经皮椎间孔镜治疗有利于提高椎间盘源性腰痛治疗效果以及减轻患者疼痛症状,减轻炎性因子反应,促进疾病恢复。 |
| 英文摘要: |
| Objective To investigate the value of self-designed Bugantongluo prescription combined with percutaneous transforaminal endoscopic discectomy in patients with discogenic low back pain, and to analyze the effects on clinical symptoms, serum 6-keto-PGF1α and related cytokines of helper T cell 17 (Th17). Methods A total of 105 patients with discogenic low back pain admitted to our hospital from March 2022 to March 2023 were divided into the control group (n=52) and the observation group (n=53) by the random number table method. The control group was treated with percutaneous transforaminal endoscopic discectomy and routine treatment, and the observation group was treated with self-designed Bugantongluo prescription on the basis of the treatment. Both groups were treated for 3 months. The efficacy, the changes of TCM syndrome scores before and after treatment, the pain and recovery of the waist and legs, and the changes of 6-keto-PGF1α and Th17 cell related cytokines of the two groups were observed, and the adverse reactions were monitored. Results ① The syndrome scores such as lumbar pain, limb numbness, waist and knee weakness, flexion and extension weakness in the observation group were lower than those in the control group after 3 months of treatment (P<0.05) ② The total effective rate in the observation group was higher than that in the control group (P<0.05); ③ After 1 month and 3 months of treatment, the visual analogue score (VAS) and Oswestry disability index (ODI) in the observation group were lower than those in the control group (P < 0.05). ④ After 3 months of treatment, the levels of 6-keto-PGF1α, Th17 cells, interleukin-6 (IL-6) and interleukin-17 (IL-17) in the observation group were lower than those in the control group (P < 0.05). ⑤ There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions Self-designed Bugantongluo prescription combined with percutaneous transforaminal endoscopic discectomy is beneficial to improve the treatment effect of discogenic low back pain, reduce the pain symptoms, reduce the inflammatory factor response, and promote the recovery of the disease. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
